News from ESC 2024: OCEANIC-AF; asundexian vs apixaban in AF

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Comments

Overview
ESC 2024 - In OCEANIC-AF, the effects of the novel factor XIa inhibitor asundexian versus apixaban were evulated in patients with AF at high stroke risk. Manesh Patel discusses the study results.
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Manesh Patel is a cardiologist at Duke Hospital in Durham, NC, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of OCEANIC-AF
Release date: 2 September 2024

Recommended

Details

Presenters

Comments

Overview
ESC 2024 - In OCEANIC-AF, the effects of the novel factor XIa inhibitor asundexian versus apixaban were evulated in patients with AF at high stroke risk. Manesh Patel discusses the study results.
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Manesh Patel is a cardiologist at Duke Hospital in Durham, NC, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of OCEANIC-AF
Release date: 2 September 2024

Factor XIa inhibitor versus DOAC in patients with AF at high stroke risk